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Abstract 
Review on t(X;14)(p22;q32) or t(Y;14)(p11;q32) 
with data on the genes involved, and clinics. 
Keywords 
IGH; CRLF2, B cell precursor Acute Lymphoblastic 
Leukemia (ALL), Ph-like, BCR/ABL1ñlike ALL. 
Clinics and pathology 
Disease 
Provisional entity: B-lymphoblastic 
leukemia/lymphoma, BCR/ABL1ñlike (Arber et al. 
2016) 
Etiology 
The translocation IGH/CRLF2 involves a CpG break 
at CRLF2 and a V(D)J break at IGH locus, and 
produce overexpression of the CRLF2 protein 
(Schmäh et al. 2017). 
Epidemiology 
Reports about the IGH/CRLF2 prevalence have been 
obtained from selected and unselected patients, 
mostly from retrospective cohorts; as a consequence 
contrasting results have been informed. The Medical 
Research Council (MRC) found IGH/CRLF2 in 1% 
of paediatric patients (Ensor et al. 2011); in adults 
with Ph-like this translocation has been detected in 
57.6% of cases (Roberts et al. 2017). A recent study 
reports in ALL  
children and adolescents (1-18 years-old) the higher 
incidence of IGH/CRLF2 in patients with median 
age of 14 years (Schmäh et al. 2017). Another report 
describes a cohort of pre B-ALL patients, ranging 
from 1-60 years-old, with IGH/CRLF2 in 37.2% of 
cases (Russell et al. 2017). In general, the prevalence 
of IGH/CRLF2 increases with age. 
Clinics 
ALL with BCP immunophenotype with 
rearrangement involving a cytokine receptor, 
included in the BCR/ABL1ñlike ALL subgroup. 
Treatment 
The IGH/CRLF2 translocation results in kinase-
activating lesion that causes the constitutive 
activation of the Jak2/STAT5 signalling pathway. 
The patients that harbour IGH/CRLF2 ALL could 
benefit from the treatment with Ruxolitinib, which 
blocks Jak2/STAT5 pathway (Figure 5).  
This treatment could potentially improve their 
survival (Harrison 2013)). 
Prognosis 
IGH/CRLF2 is associated with high risk National 
Cancer Institute (NCI) characteristics in contrast to 
P2RY8/CRLF2 positive patients. IGH/CRLF2 is 
also present in patients with high levels of minimal 
residual disease (MRD) (≥ 10-3) which are consider 
MRD-slow early responders, based on this the group 
is prone to suffer relapses (Schmäh et al. 2017; 
Attarbaschi et al. 2012). 
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Figure 1.  CRLF2 Flow cytometry analysis in an ALL patient with IGH/CRLF2 rearrangement. The figure shows the strategy 
applied to analyze by flow cytometry the CRLF2 overexpression and activation in blasts population (CD34+ CD19+), compared 
with unstained control (A). In this patient almost 100% of blasts are positive to CRLF2 protein, (B) and its signaling pathway is 
active since the phosphorylation of STAT5 at tyrosine residue (pY694) is present and (C) was reversible by the Jak2 inhibitor 
Ruxolitinib. 
 
Figure 2.  Chromosomes obtained from MHH-CALL-4 cell line positive to IGH/CRLF2 translocation detected by fluorescence in 
situ hybridization (FISH). The der(Y) chromosome is lost in the cell line. (A) Metaphase hybridized with CRLF2 break-apart probe 
(Cytocell Aquarius) with a normal chromosome X (yellow arrow) and the der(14) (green arrow). (B) Metaphase hybridized with 
IGH break-apart probe (Vysis-Abbott) with the normal chromosome 14 (yellow arrow) and the der(14) (red arrow). 
Cytogenetics 
Cytogenetics morphological 
t(X;14)(p22;q32) or t(Y;14)(p11;q32) IGH/CRLF2 
is a cryptic rearrangement (Figures 2 and 3). It is 
present in patients with extra copies of the X 
chromosome produced by high hyperdiploidy in 
19.8% of cases. To date, only one patient who 
presented both a PAR1 deletion (P2RY8/CRLF2) 
and IGH/CRLF2 translocation has been reported 
(Harvey et al. 2010). Recently, two patients with  
coexistence of IGH/CRLF2 and BCR/ ABL1 
rearrangements have been described. One patient 
presented both rearrangements in different clones 
(Russell et al. 2017); the other case showed the 
translocation t(Y;14) harbouring the CRLF2 
rearrangement in 90% of interphases, and presented 
BCR/ABL1 fusion in a subset of the CRLF2-
rearranged cells (Jain et al. 2017).  
IGH/CRLF2 positive cells also have a high 
frequency (94%) of additional deletions which may 
reflect chromosomal instability (Schmäh et al. 
2017).  
The most common deletions in addition to this 
rearrangement are found in IKZF1 (53%), ADD3 
(46%) and SLX4IP (41%). Similar to patients 
P2RY8/CRLF2 positive, deletions in JAK1/ JAK2 
(17%) are also present (Russell et al. 2017). 
Although IGH/CRLF2 is part of the BCR/ABL1-like 
ALL subtype this rearrangement is not associated 
with it in all cases; however, those patients with the 
rearrangement in coexistence with JAK2 mutations 
have been found that present the expression 
signature of the subtype (Herold et al. 2017).  
Although in Down syndrome patients the 
P2RY8/CRLF2 deletion is more frequent, 
IGH/CRLF2 rearrangement is also observed (35% 
vs. 20% respectively) (Russell et al. 2017). 
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Figure 3. (A-B) FISH in interphase nuclei with the IGH break apart-probe, and (C-D) with the CRLF2 break-apart probe. The 
yellow arrows indicate normal alleles and the red and green arrows indicate monoallelic breakages. 
 
Genes involved and 
proteins 
IGH (immunoglobulin heavy locus) 
Location 
14q32.33 
Protein-coding gene. Others names: D (diversity) 
region of heavy chains; J (joining) region of heavy 
chains; immunoglobulin heavy chain variable 
region; immunoglobulin heavy diversity group; 
immunoglobulin heavy diversity locus; 
immunoglobulin heavy joining cluster; 
immunoglobulin heavy joining group; 
immunoglobulin heavy polypeptide, joining region; 
immunoglobulin heavy variable cluster; 
immunoglobulin heavy variable group. Other 
symbols: IGHDY1; IGH@; IGD1; IGHV; IGHD@; 
IGHJ@; IGHV@; IGH1@ 
DNA/RNA 
The genomic location of IGH starts at 105,536,746 
pb from 14pter and ends in 106,879,844pb from 
14pter. The size is 1,343,098 bases, with minus 
strand orientation NC_000014.9 
CRLF2 (cytokine receptor like factor 
2) 
Location 
It is located at the PAR1 of chromosome X, 
Xp22.33, and chromosome Y, Yp11. 
Protein-coding gene. Other names and symbols: 
Thymic Stromal Lymphopoietin Protein Receptor, 
TSLP Receptor, Thymic Stromal-Derived 
Lymphopoietin Receptor, Cytokine Receptor-Like 
2. Others symbols: TSLPR, CRL2, CRLF2Y. 
DNA/RNA 
The genomic location of CRLF2 gene in 
chromosome X starts at 1,187, 549 bp from Xpter, 
and ends at 1, 212, 815 bp from Xpter. The size is 
25, 267 bases, with minus strand orientation 
NC_018934. CRLF2 has 3 transcripts variant; the 
transcript variant 1 has 1606pb mRNA 
NM_022148.2, this variant encodes the longer 
isoform NM_022148.2(Schmäh et al. 2017); the 
transcript variant 2 has 1503pb mRNA 
NM_001012288.2, this variant lacks an alternate 
exon which results in translation initiation at a 
downstream start codon compared to variant 1, the 
resulting isoform is shorter at the N-terminus 
compared to isoform 1(Russell et al. 2017); the 
transcript variant 3, uses an alternative splice 
junction at the 5¥end of an exon, and contains 
another alternate exon compared to variant 1, this 
variant is a non-coding mRNA  NR_110830.1. 
Protein 
The cytokine receptor-like factor 2 has a size of 371 
amino acids, with a molecular mass of 42013 
Daltons.  Cytokine receptor-like factor 2 is a 
transmembrane protein with an extracellular domain 
of 210 residues, and an intracellular domain of 119 
residues (Zhang et al. 2001). CRLF2 
heterodimerizes with IL7R constituting a functional 
receptor (Figure 5) (Rochman et al. 2010; Bugarin et 
al. 2015). 
Somatic mutations 
The CRLF2 711T>G (Phe232Cys) mutation has 
been found in ALL blasts. The CRLF2 Phe232 
residue is near to the junction of the extracellular and 
transmembrane domains. The Phe232Cys mutation 
confers a constitutive dimerization through the 
cysteine residues inducing cell growth. This 
mutation also promotes the up-regulation of 
downstream transcriptional targets of the 
Jak2/STAT5 pathway (Figure 5) (Yoda et al. 2010). 
Result of the chromosomal 
anomaly 
Hybrid gene 
The IGH/CRLF2 rearrangement results from a 
cryptic translocation t(X;14)(p22;q32) or 
t(Y;14)(p11;q32) involving the PAR1 region, which 
is located in the short arm of both sex chromosomes 
and the immunoglobulin heavy chain locus located 
in the chromosome 14 (Figure 3). Represent the 20-
26% of IGH translocations in B cell precursor ALL 
and the principal consequence is a deregulated 
t(X;14)(p22;q32) or t(Y;14)(p11;q32) IGH/CRLF2 
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transcription of CRLF2 by the physical juxtaposition 
with the IGH transcriptional enhancers (Figure 4) 
(Dyer et al. 2010; Chapiro et al. 2013; Jeffries et al. 
2014; Yoda et al. 2010; Tsai et al. 2010). 
Description 
IGH/CRLF2 translocation can result of an aberrant 
D-J or V-DJ recombination that involves the cryptic 
recognition signal sequence (RSS) in the 
pseudoautosomal region (Figure 4). As a result, the 
IGH-J or IGH-DJ regions becomes adjacent to the 
CRLF2 entire reading frame and the der(14) carries 
the junctions between IGH segments and the 
centromeric region of CRLF2 (Dyer et al. 2010; 
Chapiro et al. 2013; Yoda et al. 2010; Tsai et al. 
2010).  
The breakpoints occur approximately 8 to 16 Kb 
upstream to the CRLF2 translation start site and, 
there is a 311 bp cluster from positions 1,307,403 to 
1,307,713 which contains 6 out of 19 described 
breakpoints. Tsai et al., 2010 report that 7 of 19 
CRLF2 breakpoints are at 5íor 3¥sides of CpG 
dinucleotide sequences. Similar to the IGH-BCL2 
rearrangement, at least 18 of the 19 IGH breaks in 
the IGH/CRLF2 translocation are compatible with 
standard V(D)J recombination, the IGH junction is 
within 30bp 5¥of an RSS and this junctions contain 
non templated nucleotide additions consistent with 
the activity of terminal deoxynucleotide transferase 
(Dyer et al. 2010; Chapiro et al. 2013; Yoda et al. 
2010). 
Transcript 
There is no a chimeric transcript. Usually the 
rearrangement relocates the CRLF2 entire coding 
sequence without mutation under transcriptional 
control of IGH enhancer and the gene is 
overexpressed (Dyer et al. 2010). 
Detection 
The IGH/CRLF2 translocation involves the 
disruption of both loci, based on this FISH technique 
using IGH and CRLF2 break-apart probes allows the 
detection of the rearrangement (Figure 3).  
These probes mark the centromeric region of each 
gene of red color and the telomeric region of green 
color. A normal cell with intact IGH and CRLF2 
shows in each cell two close red (R) and green (G) 
fused (F) signals (2F); in a cell with the 
translocation, one normal F signal is conserved and 
one red and one green are present as a result of the 
breakage (1F1R1G pattern).  In abnormal 
metaphases the hybridization with IGH break-apart 
probe shows a der(14) with one centromeric red 
signal and one telomeric green signal moved to the 
derivative chromosome X or Y (Russell et al. 2009).  
Harvey et al. 2010 reported the IGH/CRLF2 
detection using a single fusion extra signal probe 
consisting of two bacterial artificial chromosomes 
(BAC) clones flanking CRLF2 labeled with red 
fluorochrome, and a third BAC clone centromeric to 
IGH labeled with green fluorochrome. In this assay 
an IGH/CRLF2 positive cell shows the 1F2R1G 
pattern.  
Yoda et al. 2010 amplified the IGH/CRLF2 junction 
on der(14) by PCR using a common IGHJ primer and 
spaced primers 5` of the CRLF2 coding sequence. 
 
Figure 4. The IGH/CRLF2 translocation. (A) IGH locus. The IGH breakage can occur between the variable (V-H) and diversity 
(D-H) regions, the orange diamonds represent the transcriptional enhancers. (B) PAR1 region. The breakage can occur 8Kb to 
12Kb upstream to CRLF2. (C) The derivative chromosome 14 carries the CRLF2 juxtaposition with IGH transcriptional 
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Figure 5.  PATHWAY: IGH/CRLF2 rearrangement increases the expression of CRLF2. CRLF2 signaling pathway involves the 
activation of Jak2/STAT5 and PI3k/Akt/mTOR that are related with increase in proliferation and survival of leukemic cells. Other 
cellular mechanism activated by Akt is apoptosis inhibition. Additionally, CRLF2 can activate Src family members which create a 
feedback positive loop with Abl, and activate molecules implicated in cellular adhesion and survival (TSLP Signaling Pathway 
n.d.). 
Fusion protein 
There is not a fusion protein 
Oncogenesis 
The overexpression of CRLF2 due to the 
IGH/CRLF2 translocation results in its 
homodimerization at cellular membrane. This leads 
directly to constitutive activation of JAK2/STAT5, 
PI3k/ MTOR andSRC signaling pathway, causing 
the leukemic blast proliferation and survival (Figures 
3 and 5) (Zhong et al. 2014). Nevertheless, the IGH 
translocation is not enough for the establishment of 
the neoplastic phenotype, concurrent activation of 
synergistic oncogenes and loss of tumor suppressor 
gene functions are necessary (Moorman et al. 2012). 
In the near future, inhibitors for the JAK2 pathway, 
Ruxolitinib, and for Src pathway, Dasatinib, could 
be used in order to counteract oncogenic effect 
caused by IGH/CRLF2 in ALL patients. 
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